| Patent Number |
Title Of Patent |
Date Issued |
| 6943164 |
Pharmaceutical solutions of levosimendan |
September 13, 2005 |
| Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment |
| 6903114 |
Derivatives of naphthalene with COMT inhibiting activity |
June 7, 2005 |
| Compounds of formula (I'), wherein A, R.sub.1 to R.sub.3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors. |
| 6730673 |
Pharmaceutical solutions of levosimendan |
May 4, 2004 |
| Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment |
| 6699868 |
Pyridazinyl phenyl hydrazones useful against congestive heart failure |
March 2, 2004 |
| Therapeutically active compounds of formula (I): ##STR1## in which R.sub.1 to R.sub.4 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, carboxyalkyl, hydroxyalkyl or halogenalkyl, or R.sub.2 and R.sub.3 form a ring of 5-7 carbon atoms, R.sub.5 to R.sub.9 means hydrogen, alkyl, alke |
| 6340764 |
Reference compound for use in the analysis of levosimendan batches |
January 22, 2002 |
| A pyridazinyl derivative (I) and its use as a reference compound in the determination of potentially genotoxic impurities in levosimendan samples. An analytic method for the determination of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference c |
| 6201027 |
Substituted .beta. diketones and their use |
March 13, 2001 |
| The invention relates to the compounds of formula I: ##STR1##wherein one of X.sub.1 and X.sub.2 is MeSO.sub.2 and the other one is hydrogen or halogen and X.sub.3 is hydrogen or halogen. These compounds have been found to be useful in the prevention and the treatment of respiratory d |
| 6180789 |
Method for obtaining pure enantiomers of a pyridazinone derivative |
January 30, 2001 |
| The present invention relates to a method for preparing optically active enantiomers of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]pro panedinitrile (I), particularly (-) enantiomer of (I). Furthermore, the invention relates to a novel crystalline polymorph |
| 6121303 |
Pharmacologically active catechol derivatives |
September 19, 2000 |
| A compound of formula I ##STR1## wherein R.sub.1 is nitro, halogeno or cyano group and R.sub.2 is a group selected from ##STR2## wherein Y and Z are independently oxygen, sulfur or NR, wherein R is hydrogen, straight or branched C.sub.1-8 alkyl, C.sub.5-7 cycloalkyl, phen |
| 5889037 |
Pharmacologically active catechol derivatives |
March 30, 1999 |
|
| 5614541 |
Pharmacologically active catechol derivatives |
March 25, 1997 |
| New catechol derivatives and pharmaceutically acceptable salts and esters thereof useful as pharmaceutical antioxidants are disclosed. Cellular damage by oxygen derived radicals is a significant factor in heart disease, rheumatoid arthritis, cancer, inflammatory disease, transplant r |
| 5569657 |
(-)-[[4-(1,4,5,6-tetrahydro-4-m ethyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile |
October 29, 1996 |
| The compound (-)-[[4-(1,4,5,6 tetrahydro-4-methyl-6-oxo-3 pyridazinyl) phenyl]-hydrazono] propane dinitrile and its salts are prepared and used for treating congestive heart failure. |
| 5512571 |
(-) [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydra-zono] propanedinitrile |
April 30, 1996 |
| Diastereomeric intermediate salts of formulae (IIIa) or (IIIb) ##STR1## are prepared. |
| 5424428 |
( -)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]p r |
June 13, 1995 |
| Optically substantially pure (-) enantiomer of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono)prop anedinitrile or pharmaceutically acceptable salt thereof, intermediates and a process for the preparation are described. The product is useful as a cardiotonic age |
| 5362733 |
Pharmacologically active catechol derivatives |
November 8, 1994 |
| Compounds of formula(I) ##STR1## wherein R.sub.1 is nitro, halo, cyano and R.sub.2 is a group selected from ##STR2## wherein Y is oxygen or sulfur; X.sub.1 is NR wherein R is hydrogen, C.sub.1-8 alkyl or phenyl and pharmaceutically acceptable salts thereof are useful in the p |
| 5356923 |
1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof |
October 18, 1994 |
|
| 5112861 |
Method of treating Parkinson's Disease using pentanedione derivatives |
May 12, 1992 |
| The invention concerns a method for the treatment of Parkinson's Disease. The method comprises administering a catechol-O-methyl-transferase inhibiting amount of a compound having the formula I ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, alkylcarbamoyl |
